Sandoz, a generics and biosimilar unit of Novartis, will make its generic epinephrine shots immediately available for sale in U.S. retail pharmacies as a shortage of Mylan's lifesaving allergy treatment EpiPen drags on.
Sandoz announced June 9 the retail launch of Symjepi, a single-dose, pre-filled syringe and device that is an alternative to EpiPen.
"Patients and healthcare professionals are trying to navigate this critical shortage of self-injectable epinephrine products, which is why Sandoz is immediately making Symjepi available in adult and pediatric doses to patients at their local pharmacies," said Carol Lynch, president of Sandoz.
In January, Sandoz launched Symjepi shots for use in hospitals.